MK-0366对包括耐庆大霉素铜绿假单胞菌在内的临床尿路病原体的体外活性。
In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.
作者信息
Downs J, Andriole V T, Ryan J L
出版信息
Antimicrob Agents Chemother. 1982 Apr;21(4):670-2. doi: 10.1128/AAC.21.4.670.
Abstract
MK-0366, a new derivative of nalidixic acid, was tested against 250 urinary pathogens including Escherichia coli, Serratia marcescens, and Pseudomonas aeruginosa. This new agent was more active than any of the other antibiotics tested, which included carbenicillin, ampicillin, cephalexin, tetracycline, trimethoprim, trimethoprim-sulfamethoxazole, and nalidixic acid. Gentamicin-resistant P. aeruginosa were highly sensitive to MK-0366, with a 90% minimal inhibitory concentration of 0.8 microgram/ml. Serratia strains were the most resistant organisms, with a 90% minimal inhibitory concentration of 3.1 micrograms/ml. These results suggest that clinical trials should be designed to investigate the clinical usefulness of this new drug in urinary infections.
摘要
萘啶酸的一种新衍生物MK-0366，针对250种尿路病原体进行了测试，这些病原体包括大肠杆菌、粘质沙雷氏菌和铜绿假单胞菌。这种新药物比所测试的其他任何抗生素都更具活性，所测试的其他抗生素包括羧苄青霉素、氨苄青霉素、头孢氨苄、四环素、甲氧苄啶、甲氧苄啶-磺胺甲恶唑和萘啶酸。耐庆大霉素的铜绿假单胞菌对MK-0366高度敏感，90%的最低抑菌浓度为0.8微克/毫升。沙雷氏菌菌株是最具耐药性的微生物，90%的最低抑菌浓度为3.1微克/毫升。这些结果表明，应设计临床试验来研究这种新药在尿路感染中的临床效用。
相似文献
1
In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 1982 Apr;21(4):670-2. doi: 10.1128/AAC.21.4.670.
2
Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.
Antimicrob Agents Chemother. 1982 May;21(5):848-51. doi: 10.1128/AAC.21.5.848.
3
Comparative in vitro activities of norfloxacin (MK-0366) and six commonly used antimicrobial agents against 199 urinary isolates showing various degrees of antibiotic resistance.
Diagn Microbiol Infect Dis. 1984 Apr;2(2):101-6. doi: 10.1016/0732-8893(84)90004-x.
4
Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains.
Antimicrob Agents Chemother. 1983 Oct;24(4):602-4. doi: 10.1128/AAC.24.4.602.
5
Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates.
Chemioterapia. 1984 Jun;3(3):167-72.
6
Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens.
Acta Pathol Microbiol Immunol Scand B. 1984 Apr;92(2):101-6. doi: 10.1111/j.1699-0463.1984.tb02802.x.
7
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
Antimicrob Agents Chemother. 1982 Jul;22(1):23-7. doi: 10.1128/AAC.22.1.23.
8
Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.
Diagn Microbiol Infect Dis. 1983 Jun;1(2):165-72. doi: 10.1016/0732-8893(83)90047-0.
9
Antibacterial activity of norfloxacin.
Antimicrob Agents Chemother. 1983 Jan;23(1):15-8. doi: 10.1128/AAC.23.1.15.
10
Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.
Infection. 1982 Jan;10(1):41-4. doi: 10.1007/BF01640837.
引用本文的文献
1
Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit.
Trans Am Ophthalmol Soc. 1984;82:75-91.
2
Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora.
Antimicrob Agents Chemother. 1984 Oct;26(4):481-4. doi: 10.1128/AAC.26.4.481.
3
Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains.
Antimicrob Agents Chemother. 1983 Oct;24(4):602-4. doi: 10.1128/AAC.24.4.602.
4
In vitro activity of norfloxacin against Mycoplasma hominis and Ureaplasma urealyticum.
Eur J Clin Microbiol. 1983 Oct;2(5):479-80. doi: 10.1007/BF02013911.
5
Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.
Antimicrob Agents Chemother. 1983 Aug;24(2):302-4. doi: 10.1128/AAC.24.2.302.
6
Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacin.
J Clin Microbiol. 1983 Oct;18(4):988-91. doi: 10.1128/jcm.18.4.988-991.1983.
7
In vitro and in vivo antibacterial activity of AT-2266.
Antimicrob Agents Chemother. 1983 Jul;24(1):78-84. doi: 10.1128/AAC.24.1.78.
8
Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.
Antimicrob Agents Chemother. 1983 Jul;24(1):54-60. doi: 10.1128/AAC.24.1.54.
9
Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections.
Eur J Clin Microbiol. 1983 Jun;2(3):266-9. doi: 10.1007/BF02029530.
10
Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections.
Eur J Clin Microbiol. 1983 Jun;2(3):260-5. doi: 10.1007/BF02029529.
本文引用的文献
1
Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 1981 Aug;20(2):265-6. doi: 10.1128/AAC.20.2.265.
2
Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.
Antimicrob Agents Chemother. 1981 Jan;19(1):188-9. doi: 10.1128/AAC.19.1.188.
3
In vitro antibacterial activity of a new 1-oxa cephalosporin compound.
Yale J Biol Med. 1980 Mar-Apr;53(2):149-59.
4
In vitro antibacterial activity of AM-715, a new nalidixic acid analog.
Antimicrob Agents Chemother. 1980 Feb;17(2):103-8. doi: 10.1128/AAC.17.2.103.
5
Pipemidic acid: its activities against various experimental infections.
Antimicrob Agents Chemother. 1976 Apr;9(4):569-74. doi: 10.1128/AAC.9.4.569.
Zotero 插件